Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Docetaxel by Zhuhai Beihai Biotech for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According...
Docetaxel by Zhuhai Beihai Biotech for Non-Small Cell Lung Cancer: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to...
Docetaxel by Zhuhai Beihai Biotech for Gastric Cancer: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Gastric Cancer. According to GlobalData, Pre-Registration...
Docetaxel by Zhuhai Beihai Biotech for Prostate Cancer: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Prostate Cancer. According to GlobalData, Pre-Registration...
Docetaxel by Zhuhai Beihai Biotech for Breast Cancer: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Pre-Registration for Breast Cancer. According to GlobalData, Pre-Registration...
Cabazitaxel by Zhuhai Beihai Biotech for Prostate Cancer: Likelihood of Approval
Cabazitaxel is under clinical development by Zhuhai Beihai Biotech and currently in Phase II for Prostate Cancer. According to GlobalData,...
Docetaxel by Zhuhai Beihai Biotech for Solid Tumor: Likelihood of Approval
Docetaxel is under clinical development by Zhuhai Beihai Biotech and currently in Phase III for Solid Tumor. According to GlobalData,...